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Abstract 
Spontaneous neoplasm metastasis, a fatalist pathological feature of cancer, is a 
long-evolving, multi-steps process that can now only be treated or controlled by 
drugs or immuno-modulators. As we have previously hypothesized, each drug 
or immuno-modulator might act differently within various stages of a metastasis. 
Therefore any researches helping to determine these differences will be 
beneficial for updating therapeutics for metastasis. In this work, we have 
testified this hypothesis by using a series of well-known anti-metastatic agents – 
Bisdioxopiperazine compounds. 
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Introduction 
There have been two most difficult problems in cancer biology and therapeutics, neoplasm 
metastasis and multi-drug-resistances (MDR). Among these two thorny problems, 14 D.-Y.  Lu  et al.:  
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treatments of neoplasm metastasis are especially difficulty and should be placed on higher 
agenda of the highest for its fatalist pathogenesis features and unpredictability of 
therapeutic outcome at the stage of drug initiation. Also, metastasized tumors often 
concomitantly manifest the characters of MDR. Therapeutic reports of metastasis 
treatment nowadays are overwhelmed with researches and applications of antivascular 
(angiogenesis) and MMPs inhibitors and more than 300 agents of different chemical 
formulae have been mentioned in the literatures [1–3]. Currently, all FDA licensed or 
internationally available anti-metastatic drugs share such characteristics and are regarded 
as a universal pathway for these drugs. However, these types of drugs are far from 
success in practical usage. Unfavorable reports are also enumerated such as 
indiscriminative molecular inhibition and generally low benefits for patients’ survival. More 
importantly, these therapies are also not without toxicity [4]. Unfortunately failures occur in 
most of the cases. Therefore how to optimistically use of these drugs in metastasis 
treatments remains to be a great challenge and any small breakthrough in this area will 
lead to great clinical achievements in cancer therapies.  
Tumor metastases involve a fixed course of pathophysiological processes, and are 
responsible for more than 60% of cancer deaths worldwide [5–7]. Spontaneous neoplasm 
metastasis is a long pathogenesis process to deteriorate the hosts in natural conditions, at 
least a week-long course in mice and a month-long course in human. It encompasses at 
least three main different substages:  
(i) tumor detachment from primary location;  
(ii) tumor cells flow in the blood or lymphatic vessels;  
(iii) tumor cell attachment and penetration through blood vessels of distant organs 
and angiogenesis [5].  
We have previously hypothesized that many anti-cancer or anti-metastatic drugs might act 
differently in the different courses of these substages [8]. In order to testify this hypothesis, 
we carried out an experiment to compare the inhibition of drugs against an established 
model, Lewis lung carcinoma (3LL), for observing spontaneous metastasis inhibitions 
using different therapeutic protocols. 
Bisdioxopiperazine compounds (Biz), including ICRF-154, Razoxane (ICRF-159, Raz), 
ICRF-186 and ICRF-187 (two stereo-isomers of Raz) and ICRF-193, developed in the UK, 
have been a series of serendipitous agents found to be effective against a model of 
spontaneous metastasis (Lewis lung carcinoma, 3LL) [9, 10]. Ever since their development 
in 1969, many studies have addressed their potential use and mechanisms of action. 
Since Biz compounds are unique and conservative in pharmacological actions, their new 
analogs Probimane [4,4'-propane-1,2-diylbis[1-(morpholin-4-ylmethyl)piperazine-
2,6-dione]; AT-2153, Pro] [7–10] and Bimolane [4,4'-ethane-1,2-diylbis[1-(morpholin-4-
ylmethyl)piperazine-2,6-dione]; AT-1727, Bim] [11–16] were synthesized at the Shanghai 
Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. The 
structural formula of these three Biz analogs is represented in Figure 1.  
The researches of anti-metastatic drugs, though at the odds nowadays facing, will be the 
hottest spot and discipline in the future. This work is among this very phase of great 
transitions of understanding and knowledge about metastasis treatments from drug 
discovery only into clinical drug options in combinations with.    Different Spontaneous Pulmonary Metastasis Inhibitions against Lewis Lung Carcinoma …  15 
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Fig. 1.   The structural formulae of three bisdioxopiperazine compounds 
Materials and methods 
Drugs and Reagents: Pro, Bim and Raz were prepared by Prof Yun-Feng Ren at the 
Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese 
Academy of Science and suspended in 5  g/L carboxymethylcelluose (CMC) solution 
before use.  
Animals and Tumor Models: C57BL/6j strain mice were purchased from Shanghai Center 
of Laboratory Animal Breeding, Chinese Academy of Sciences and were conducted 
experimentations in compliance with the Guidelines for the Care and Use of Research 
Animals, NIH, established by Washington University’s Animal Studies Committee.  
Neoplasm Metastases Determination: Since anti-metastatic therapeutic would be rather 
preventive than indiscrimination cytotoxic against normal and neoplasm tissues, we used a 
low dosage of Biz compounds (1/10 to 1/5 LD50) to basically offset a possible lethal or 
mutational toxicity of conventional therapies involved in such experimental study. 
Biological inoculation with pulmonary nodules of 3LL was a method used by Yue et al [14]. 
C57BL/6j mice were implanted sc with LLC (2×10
6 cells) from donor mice. The experiment 
was undergone in two different sets of schedules for day2 and day8 initiation of therapy. 
Either from day2 or day8 after tumor inoculation, the mice were injected ip with drugs daily 
in 10 injections. On day 18, all mice were sacrificed, and locally grown tumors were 
separated from skin and muscles and weighed. The 10 lungs of 5 host mice of each group 
were sterilely homogenized with sterilized normal saline (2 ml). These homogenized lungs 16 D.-Y.  Lu  et al.:  
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were separately injected sc into 10 healthy C57BL/6j mice. The numbers of mice with 
newly locally grown tumors were counted after 1 month later.  
Statistics 
Samples were subjected to statistical analysis for distinguishing between treated and 
control. 
Results 
We used the doses of 1/10 and 1/5 LD50 (from the unpublished experimental data of 
Shanghai Institute of Materia Medica, Chinese Academy of Sciences) in the following 
therapeutic experiment.  
Tab. 1.  The effects of Biz on pulmonary metastasis of Lewis lung carcinoma. 
Compounds Dosage 
ip×10  
Initial 
treated/d 
PTI%
a MNMCST
b 
Control –  –  –  9.5±0.6 
Probimane 12  2  18.6 1.5±0.2** 
Probimane 24  2  20.3 1.0±0.2** 
Probimane 12  8  19.2 1.5±0.2** 
Probimane 24  8  21.0 1.0±0.0** 
Bimolane   6.5 2  18.3  3.5±0.2* 
Bimolane 13  2  20.1  3.5±0.2* 
Bimolane   6.5 8  13.1  4.0±0.4* 
Bimolane 13  8  18.2  4.0±0.4* 
Razoxane   6.5  2  19.2  1.5±0.2** 
Razoxane 13  2  22.0  1.5±0.2** 
Razoxane   6.5  8  15.0  9.0±0.0 
Razoxane 13  8  15.8  8.5±0.8 
Ten mice were used for each group, and each group was repeated once; 
*P<0.05; **P<0.01; 
a PTI … primary tumor inhibition; 
b MNMCST … 
mean number of mice carrying secondary tumors 
 
The Effects of Biz on Pulmonary Metastasis of 3LL: Table 1 showed that Pro and Bim 
significantly inhibited the pulmonary metastasis of 3LL both following day2 and day8 
injections, but Raz only significantly inhibited the pulmonary metastasis of 3LL following 
day2 injections. Pro inhibited the pulmonary metastasis of 3LL more potently than Bim did 
at equitoxic dosage. Comparatively, it seems that Pro has superior inhibition of pulmonary 
metastasis of 3LL than Bim and Raz for its exclusive targeting potential. 
Discussion  
Since tumor metastasis is responsible for more than 60% cancer death worldwide, 
metastasis therapy, as a result, remains to be a biggest challenge to all cancer 
therapeutics. Biz compounds are well-known for their anti-metastasis action. However, 
their modes of action and therapeutic profile remain to be investigated for their potential 
clinical availability. The research work for data has been mostly focusing on anti-  Different Spontaneous Pulmonary Metastasis Inhibitions against Lewis Lung Carcinoma …  17 
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angiogenesis action [18–20] and others of sialic acids or fibrinogen-pathway inhibitions 
[21, 22]. Different inhibitory characteristics of the three Biz compounds, Bim, Raz and Pro 
to pulmonary metastasis of 3LL were evidences from the results of this experiment. The 
major difference between Raz and Pro is that Raz treated day8 after the tumor inoculation 
showed simply no inhibition on pulmonary metastasis of 3LL. In contrary, Pro or Bim may 
have a wider therapeutic maintenance than Raz. It suggests that the morpholine group 
presented in structures may play a role for their potential treatments of formed metastatic 
foci. Two previous data of our experimentations can support and explain this evidence of 
great divergence of metastasis inhibition between different Biz compounds and treatment 
schedules. Pro has a better therapeutic index than Bim although they may act through 
same pathways and have similar molecular targets. The development of pathogeneses of 
tumor metastasis has be categorized further into three critical steps; (i) tumor detachment 
from primary location; (ii) tumor cells flow in the blood or lymphatic vessels; (iii) tumor cell 
attachment and penetration through blood vessels of distant organs. From the report of 
James et al, the detachment of 3LL began at day 6–8 [23]. The inhibition of neoplasm 
metastasis by Raz has been previously explained as a result of reducing in the formation 
of blood vessels in tumor tissues (neovasculature) [18–20]. This study further supports this 
mechanism by reiterating with targeting for tumor cell detachment from primary sites. 
Thus, it has been proposed that Raz remains ineffective against the pulmonary 
metastases of 3LL (formed metastatic foci). This data can be used to explain also why Raz 
was reported to be more effective against neoplasm metastases for spontaneous 
metastatic tumors rather than for artificial ones [2]. However, Pro and Bim might be equally 
effective in both the cases. From our early data of 
14C-probimane tracing and 
autoradiography [24,  25], an obvious greater accumulation of Pro was found in tumor 
tissues, especially in metastatic foci. It can help to explain that Pro can more effectively 
inhibition of neoplasm metastasis than Raz in formed metastatic foci through stronger 
antiproliferative effect [13, 14]. Their molecular mechanisms of action may be attributed to 
their inhibition of CaM-activated Ca
++-Mg
++-ATPase [26].  
This experimental evidence further supports our hypothesis that each drug or immuno-
modulators might act differently within various stages of a metastatic course. In general, 
we propose that the MMPs inhibitors might be more active in preventing tumor cells from 
detaching from primary locations. Immuno-modulators might promote the activity of 
macrophages in killing of tumor cells in vascular and lymphatic circulation [27]. However, 
highly cytotoxicity agents, alone or in combination with angiogenesis inhibitors might be 
more effective in treatment of formed metastatic foci. It helps us to better use the drugs in 
treating cancer metastases in the future. 
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